.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,974,595

« Back to Dashboard
Patent 6,974,595 protects CAMBIA and is included in one NDA. There has been one Paragraph IV challenge on Cambia.

This patent has thirty-two patent family members in twenty-four countries.

Summary for Patent: 6,974,595

Title: Pharmaceutical compositions based on Diclofenae
Abstract:New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher C.sub.max of the active principle and shorter T.sub.max together with a lower coefficient of variation.
Inventor(s): Reiner; Alberto (Como, IT), Reiner; Giorgio (Como, IT)
Assignee: ProEthic Pharmaceuticals, Inc. (Montgomery, AL)
Application Number:09/524,747
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 2nd percentile
Forward Citations: 5th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Depomed Inc
CAMBIA
diclofenac potassium
FOR SOLUTION;ORAL022165-001Jun 17, 2009RXYes6,974,595► subscribe ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,974,595

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI96A0992May 17, 1996

Non-Orange Book Patents for Patent: 6,974,595

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,687,542Rapidly bioavailable tablet and capsule formulations of diclofenac► subscribe
7,482,377Pharmaceutical compositions and methods of treatment based on diclofenac► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,974,595

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina007165► subscribe
Austria210976► subscribe
Austria229801► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc